StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)

Equities research analysts at StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report issued on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Maxim Group cut their price objective on shares of Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 12th.

Moleculin Biotech Stock Down 1.9 %

Shares of NASDAQ MBRX opened at $1.51 on Friday. The business has a fifty day moving average price of $2.03 and a two-hundred day moving average price of $2.45. Moleculin Biotech has a fifty-two week low of $1.46 and a fifty-two week high of $10.35.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.